EMC Capital Management Purchases 26,134 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

EMC Capital Management raised its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 142.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,535 shares of the company’s stock after purchasing an additional 26,134 shares during the quarter. EMC Capital Management owned 0.13% of Reviva Pharmaceuticals worth $81,000 at the end of the most recent reporting period.

Separately, Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $36,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Stock Performance

RVPH opened at $1.89 on Friday. The company’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $1.35. Reviva Pharmaceuticals Holdings, Inc. has a 1-year low of $0.60 and a 1-year high of $4.83.

Analysts Set New Price Targets

A number of analysts have weighed in on RVPH shares. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. HC Wainwright cut their price target on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $11.40.

Reviva Pharmaceuticals Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.